Trial reportAmerican journal of respiratory and critical care medicine2020
Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Impact of dose and administration schedule on biologic efficacy in chronic rhinosinusitis with nasal polyps: a network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Biologics and Surgery in Chronic Rhinosinusitis With Nasal Polyps: A Comparative Outcomes Analysis.American journal of rhinology & allergy · 2025Pooled it
- Biologics for chronic rhinosinusitis.The Cochrane database of systematic reviews · 2021Pooled it
- Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease.Clinical and translational allergy · 2026Review
- Review
- New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report.Clinical and translational allergy · 2026Review
- Toward precision medicine in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.ERJ open research · 2026Article
- Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications-An EAACI Task Force Report.Allergy · 2026Article
- Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Biologic therapies targeting type 2 inflammation in NSAID-exacerbated respiratory disease.Frontiers in immunology · 2026Review
- Off-label applications of omalizumab: Current insights and perspectives.The World Allergy Organization journal · 2025Review
- The Expanding Role of Omalizumab: From Food Allergy to Drug Desensitization.International journal of molecular sciences · 2025Review
- Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps.The Journal of allergy and clinical immunology · 2025Review
- Clinical and mechanistic advancements in aspirin exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2025Review
- TGF-β drives differentiation of intraepithelial mast cells in inflamed airway mucosa.The Journal of clinical investigation · 2025Article
- Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study.Frontiers in immunology · 2025Article
- Anti-IgE therapy in chronic rhinosinusitis with nasal polyps.The Journal of allergy and clinical immunology · 2025Review
- Efficacy of Biologics in NSAID-ERD: United Airways From the Nose to the Bronchi.The journal of allergy and clinical immunology. In practice · 2024Review
- Article
- [Expert consensus on the diagnosis and treatment of respiratory diseases exacerbated by nonsteroidal anti-inflammatory drugs （2024, Chengdu）].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2024Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 1 country.
Hiroaki HayashiClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Yuma FukutomiClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.ORCID 0000-0001-9913-4524
Chihiro MitsuiClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Keiichi KajiwaraClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Kentaro WataiClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.ORCID 0000-0001-9490-864X
Yosuke KamideClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Yuto NakamuraClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Yuto HamadaClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Yasuhiro TomitaClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Kiyoshi SekiyaClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Takahiro TsuburaiClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Kenji IzuharaDivision of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan; and.
Keiko WakaharaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-7281-6760
Naozumi HashimotoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshinori HasegawaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masami TaniguchiClinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
National Sagamihara Hospital · JPNagoya University · JPJuntendo University · JPSaga Medical School Hospital · JPSt. Marianna University School of Medicine · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAnti-Allergic AgentsAnti-Inflammatory Agents, Non-SteroidalArea Under CurveAspirinAsthma, Aspirin-InducedCross-Over StudiesDouble-Blind MethodFemaleForced Expiratory VolumeHumansLeukotriene E4MaleMiddle AgedOmalizumab11,15-dioxo-9-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acidAnti-Allergic AgentsAnti-Inflammatory Agents, Non-SteroidalAspirinLeukotriene E4OmalizumabProstaglandin D2aspirin-exacerbated respiratory diseaseaspirin hypersensitivityaspirin toleranceleukotriene E4omalizumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.